(VCYT) Veracyte - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: NASDAQ (USA) | Market Cap: 3.606m USD | Total Return: 58.1% in 12m
Avg Turnover: 40.9M
Qual. Beats: 1
Rev. Trend: 99.7%
Qual. Beats: 5
Warnings
Altman Z'' -2.33 < 1.0 - financial distress zone
Tailwinds
Confidence
Veracyte, Inc. is a diagnostics company specializing in genomic testing to improve clinical decision-making across several oncology indications, including thyroid, prostate, bladder, breast, and lung cancers. Headquartered in South San Francisco, the firm utilizes high-resolution genomic sequencing and proprietary bioinformatics to reduce diagnostic ambiguity and minimize unnecessary invasive procedures.
The company operates within the precision medicine sector, where business models typically rely on high-margin laboratory developed tests (LDTs) and securing reimbursement coverage from private insurers and Medicare. Veracyte also leverages its acquisition of the nCounter analysis system to provide diagnostic services and expand its global footprint through decentralized testing kits. To better understand the long-term financial health of this biotech firm, consider reviewing the fundamental metrics on ValueRay.
- Afirma and Decipher test volume growth drives core diagnostic revenue expansion
- Medicare reimbursement rate changes impact clinical service gross margins
- Successful integration of acquired genomic technologies accelerates global market penetration
- Regulatory approval timelines for lung cancer nasal swab test influence valuation
- Expansion of nCounter analysis system services diversifies international recurring revenue streams
| Net Income: 88.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.81 > 1.0 |
| NWC/Revenue: 86.03% < 20% (prev 66.47%; Δ 19.56% < -1%) |
| CFO/TA 0.12 > 3% & CFO 166.2m > Net Income 88.0m |
| Net Debt (-399.7m) to EBITDA (106.1m): -3.77 < 3 |
| Current Ratio: 9.31 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.3m) vs 12m ago 1.57% < -2% |
| Gross Margin: 71.31% > 18% (prev 0.68%; Δ 7.06k% > 0.5%) |
| Asset Turnover: 39.37% > 50% (prev 35.23%; Δ 4.15% > 0%) |
| Interest Coverage Ratio: 84.6k > 6 (EBITDA TTM 106.1m / Interest Expense TTM 1.00k) |
| A: 0.32 (Total Current Assets 522.2m - Total Current Liabilities 56.1m) / Total Assets 1.44b |
| B: -0.24 (Retained Earnings -348.9m / Total Assets 1.44b) |
| C: 0.06 (EBIT TTM 84.6m / Avg Total Assets 1.38b) |
| D: -3.88 (Book Value of Equity -357.1m / Total Liabilities 92.0m) |
| Altman-Z'' = -2.33 = D |
| DSRI: 0.80 (Receivables 50.1m/53.8m, Revenue 541.7m/463.4m) |
| GMI: 0.95 (GM 71.31% / 68.02%) |
| AQI: 0.91 (AQ_t 0.60 / AQ_t-1 0.66) |
| SGI: 1.17 (Revenue 541.7m / 463.4m) |
| TATA: -0.05 (NI 88.0m - CFO 166.2m) / TA 1.44b) |
| Beneish M = -3.22 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 44.21 with a total of 928,154 shares traded.
Over the past week, the price has changed by +6.53%,
over one month by +30.61%,
over three months by +14.09% and
over the past year by +58.06%.
Veracyte has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy VCYT.
- StrongBuy: 8
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 47.4 | 7.2% |
P/E Trailing = 41.8426
P/E Forward = 26.2467
P/S = 6.656
P/B = 2.6797
Revenue TTM = 541.7m USD
EBIT TTM = 84.6m USD
EBITDA TTM = 106.1m USD
Long Term Debt = 35.0m USD (estimated: total debt 39.3m - short term 4.35m)
Short Term Debt = 4.35m USD (from shortTermDebt, last quarter)
Debt = 39.3m USD (from shortLongTermDebtTotal, last quarter) (leases 39.3m already included)
Net Debt = -399.7m USD (calculated: Debt 39.3m - CCE 439.1m)
Enterprise Value = 3.21b USD (3.61b + Debt 39.3m - CCE 439.1m)
Interest Coverage Ratio = 84.6k (Ebit TTM 84.6m / Interest Expense TTM 1.00k)
EV/FCF = 20.71x (Enterprise Value 3.21b / FCF TTM 154.8m)
FCF Yield = 4.83% (FCF TTM 154.8m / Enterprise Value 3.21b)
FCF Margin = 28.58% (FCF TTM 154.8m / Revenue TTM 541.7m)
Net Margin = 16.25% (Net Income TTM 88.0m / Revenue TTM 541.7m)
Gross Margin = 71.31% ((Revenue TTM 541.7m - Cost of Revenue TTM 155.4m) / Revenue TTM)
Gross Margin QoQ = 72.32% (prev 74.43%)
Tobins Q-Ratio = 2.23 (Enterprise Value 3.21b / Total Assets 1.44b)
Interest Expense / Debt = 0.00% (Interest Expense 1.00k / Debt 39.3m)
Taxrate = 4.23% (1.27m / 30.0m)
NOPAT = 81.0m (EBIT 84.6m * (1 - 4.23%))
Current Ratio = 9.31 (Total Current Assets 522.2m / Total Current Liabilities 56.1m)
Debt / Equity = 0.03 (Debt 39.3m / totalStockholderEquity, last quarter 1.34b)
Debt / EBITDA = -3.77 (Net Debt -399.7m / EBITDA 106.1m)
Debt / FCF = -2.58 (Net Debt -399.7m / FCF TTM 154.8m)
Total Stockholder Equity = 1.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.40% (Net Income 88.0m / Total Assets 1.44b)
RoE = 5.39% (Net Income TTM 88.0m / Total Stockholder Equity 1.63b)
RoCE = 5.08% (EBIT 84.6m / Capital Employed (Equity 1.63b + L.T.Debt 35.0m))
RoIC = 6.18% (NOPAT 81.0m / Invested Capital 1.31b)
WACC = 9.29% (E(3.61b)/V(3.65b) * Re(9.39%) + D(39.3m)/V(3.65b) * Rd(0.00%) * (1-Tc(0.04)))
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 4.84%
[DCF] Terminal Value 74.99% ; FCFF base≈124.3m ; Y1≈142.4m ; Y5≈209.6m
[DCF] Fair Price = 38.94 (EV 2.71b - Net Debt -399.7m = Equity 3.11b / Shares 79.8m; r=9.29% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.42 | # QB: 1
Revenue Correlation: 99.68 | Revenue CAGR: 20.13% | SUE: 2.27 | # QB: 5
EPS current Quarter (2026-06-30): EPS=0.43 | Chg30d=+4.14% | Revisions=+60% | Analysts=10
EPS next Quarter (2026-09-30): EPS=0.43 | Chg30d=-0.64% | Revisions=+0% | Analysts=10
EPS current Year (2026-12-31): EPS=1.82 | Chg30d=+10.61% | Revisions=+60% | GrowthEPS=+2.5% | GrowthRev=+13.3%
EPS next Year (2027-12-31): EPS=1.91 | Chg30d=+7.41% | Revisions=+60% | GrowthEPS=+4.4% | GrowthRev=+11.8%
[Analyst] Revisions Ratio: +60%